跳转至内容
Merck
CN
所有图片(1)

主要文件

查看所有文档

SML1026

Sigma-Aldrich

Lasofoxifene tartrate

≥98% (HPLC)

别名:

(-)-cis-6-Phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol tartrate, (5R,6S)-5,6,7,8-Tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-naphthalenol tartrate, CP-336,156 tartrate

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C28H31NO2 · C4H6O6
CAS号:
190791-29-8
分子量:
563.64
UNSPSC代码:
51111800
PubChem化学物质编号:
329825634
NACRES:
NA.77

质量水平

100

方案

≥98% (HPLC)

表单

powder

储存条件

desiccated

颜色

white to beige

溶解性

DMSO: 10 mg/mL, clear

储存温度

2-8°C

SMILES字符串

OC1=CC=C(C(CC[C@@H]2C3=CC=CC=C3)=C1)[C@H]2C4=CC=C(OCCN5CCCC5)C=C4.O=C(O)[C@@H](O)[C@H](O)C(O)=O

InChI

1S/C28H31NO2.C4H6O6/c30-24-11-15-27-23(20-24)10-14-26(21-6-2-1-3-7-21)28(27)22-8-12-25(13-9-22)31-19-18-29-16-4-5-17-29;5-1(3(7)8)2(6)4(9)10/h1-3,6-9,11-13,15,20,26,28,30H,4-5,10,14,16-19H2;1-2,5-6H,(H,7,8)(H,9,10)/t26-,28+;1-,2-/m10/s1

InChI key

INEHJXCWEVNEDZ-LUDNRVPPSA-N

生化/生理作用

Lasofoxifene is a selective estrogen receptor modulator (SERM).
Lasofoxifene is a third-generation selective estrogen receptor modulator (SERM).
Lasofoxifene possesses strong resistance to intestinal wall glucuronidation and thus promotes oral bioavailability. In postmenopausal women, it reduces bone resorption, bone loss and low density lipoprotein (LDL) cholesterol. Selective and regular dose of Lasofoxifene is known to reduce the risk of fractures, breast cancer, major coronary heart disease, and stroke.

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000237043
0000237043
0000197232
0000197232
0000029739

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Lasofoxifene in postmenopausal women with osteoporosis.
Cummings S R, et al.
The New England Journal of Medicine, 362(8), 686-696 (2010)
Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis.
Gennari L, et al.
Expert Opinion on Investigational Drugs, 15(9), 1091-1103 (2006)
Nam Sook Kim et al.
Journal of pharmaceutical and biomedical analysis, 179, 113003-113003 (2019-12-10)
The aim of this study was to simultaneously determine the presence of unauthorized drug substances in health foods and herbal products used in the treatment of conditions such as gout and anti-osteoporosis. Therefore, we developed and optimised a rapid and
Kaitlyn J Andreano et al.
Breast cancer research and treatment, 180(3), 635-646 (2020-03-05)
The combination of targeting the CDK4/6 and estrogen receptor (ER) signaling pathways with palbociclib and fulvestrant is a proven therapeutic strategy for the treatment of ER-positive breast cancer. However, the poor physicochemical properties of fulvestrant require monthly intramuscular injections to
Nam Sook Kim et al.
Journal of separation science, 43(14), 2750-2765 (2020-04-17)
An analytical method for the simultaneous and reliable determination of 20 antigout and antiosteoporosis pharmaceutical compounds in adulterated health food products was developed using liquid chromatography with electrospray ionization tandem mass spectrometry and liquid chromatography with quadrupole-time-of-flight mass spectrometry. The

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门